tirzepatide court case FDA's decision creates uncertainty for patients—and leads to a lawsuit FDA Can Keep Tirzepatide off

Dry mouth (xerostomia) Reduced salivary flow is one of the most common complaints I hear from patients on GLP-1 medications, she said

Therefore, regulation of intracellular GSH level is a promising strategy to boost the efficacy of antitumor treatment, as the exhaustion of antioxidants is highly desirable to sensitize cancer cells to various therapeutic means, such as chemotherapy, photodynamic therapy (PDT), chemodynamic therapy (CDT), and radiotherapy

24

No fees, as long as you pay on time

However, other countries with no specific BMI requirement also register low use of GLP-1 RAs, suggesting that the cost limitation could not be a major obstacle in its wider uptake [18, 42]

Biol Psychiatry 2008, 64(5):361368